CN113975457A - Wound repair gel, wound autoblood repair gel and preparation method - Google Patents
Wound repair gel, wound autoblood repair gel and preparation method Download PDFInfo
- Publication number
- CN113975457A CN113975457A CN202110858408.2A CN202110858408A CN113975457A CN 113975457 A CN113975457 A CN 113975457A CN 202110858408 A CN202110858408 A CN 202110858408A CN 113975457 A CN113975457 A CN 113975457A
- Authority
- CN
- China
- Prior art keywords
- gel
- wound
- solution
- group
- repair gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008439 repair process Effects 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 230000037314 wound repair Effects 0.000 title claims description 63
- 238000001879 gelation Methods 0.000 title abstract description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 50
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 50
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 50
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 42
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 35
- 239000000463 material Substances 0.000 claims abstract description 27
- 239000000654 additive Substances 0.000 claims abstract description 26
- 230000000996 additive effect Effects 0.000 claims abstract description 25
- 239000008103 glucose Substances 0.000 claims abstract description 24
- -1 compound amino acid Chemical class 0.000 claims abstract description 23
- 102000004877 Insulin Human genes 0.000 claims abstract description 21
- 108090001061 Insulin Proteins 0.000 claims abstract description 21
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 21
- 229940125396 insulin Drugs 0.000 claims abstract description 21
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 11
- 206010052428 Wound Diseases 0.000 claims description 97
- 208000027418 Wounds and injury Diseases 0.000 claims description 97
- 239000000243 solution Substances 0.000 claims description 87
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 39
- 210000004369 blood Anatomy 0.000 claims description 38
- 239000008280 blood Substances 0.000 claims description 38
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 32
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 229940024606 amino acid Drugs 0.000 claims description 27
- 239000007864 aqueous solution Substances 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 26
- 230000004663 cell proliferation Effects 0.000 claims description 25
- 230000002924 anti-infective effect Effects 0.000 claims description 24
- 235000015097 nutrients Nutrition 0.000 claims description 22
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 20
- 229920002125 Sokalan® Polymers 0.000 claims description 20
- 229960001631 carbomer Drugs 0.000 claims description 20
- 238000006213 oxygenation reaction Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 229920001503 Glucan Polymers 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 16
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 16
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 16
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 16
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 16
- 239000004472 Lysine Substances 0.000 claims description 16
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 16
- 239000004473 Threonine Substances 0.000 claims description 16
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 16
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 16
- 229960000310 isoleucine Drugs 0.000 claims description 16
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 16
- 229930182817 methionine Natural products 0.000 claims description 16
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 16
- 239000004474 valine Substances 0.000 claims description 16
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 15
- 229930182566 Gentamicin Natural products 0.000 claims description 15
- 229960002518 gentamicin Drugs 0.000 claims description 15
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 14
- 239000001110 calcium chloride Substances 0.000 claims description 14
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 14
- 239000001103 potassium chloride Substances 0.000 claims description 14
- 235000011164 potassium chloride Nutrition 0.000 claims description 14
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 14
- 239000004299 sodium benzoate Substances 0.000 claims description 14
- 235000010234 sodium benzoate Nutrition 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 13
- 230000029663 wound healing Effects 0.000 claims description 11
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 10
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 9
- 229920002498 Beta-glucan Polymers 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 8
- 229960001031 glucose Drugs 0.000 claims description 7
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 7
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 6
- 210000000601 blood cell Anatomy 0.000 claims description 5
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 15
- 230000035876 healing Effects 0.000 abstract description 9
- 239000000499 gel Substances 0.000 description 122
- 238000012360 testing method Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000001684 chronic effect Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 208000008960 Diabetic foot Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 230000007969 cellular immunity Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 238000006757 chemical reactions by type Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
- A61L2300/214—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A wound repairing gel, wound autoblood repairing gel and preparation method thereof are provided. The preparation material of the repair gel comprises: adding compound amino acid, glucose, polyvinyl alcohol and insulin according to the weight ratio; polyvinylpyrrolidone and gel additive are added according to the volume ratio. The technical scheme provided by the application can effectively promote the rapid repair of the cells of the wound surface, improve the speed of wound surface healing and improve the effect of wound surface repair.
Description
Technical Field
The invention relates to a wound repair gel, belonging to the technical field of wound repair; the invention also relates to a wound autoblood repair gel; the invention also relates to a preparation method of the wound repair gel; the invention also relates to a preparation method of the wound autoblood repair gel.
Background
Chronic refractory wounds are a result of various causes of destruction of skin integrity and normal tissue and loss of skin function. In recent years, with the development of aging of the global population, the frequent occurrence of diabetes, vascular diseases and senile chronic diseases, the incidence rate of refractory wounds is increasing, and the refractory wounds become important chronic diseases which seriously affect the life health of people. According to statistics, about 1% of patients with refractory wounds are in the world, and the medical cost of the patients is up to 5% of the total medical cost. The chronic refractory wound is not healed for a long time, thus seriously affecting the original disease recovery and the life quality of patients and bringing heavy nursing and economic burden to families. Ulcer canceration can occur on a few chronic difficult-to-heal wound surfaces. If infection spread occurs on the chronic wound surface which is difficult to heal, sepsis and other complications can be caused, the primary disease is aggravated, and even the life of a patient is threatened. The generation mechanism of the chronic wound surface which is difficult to heal is complex, and is not completely clarified so far. Clinical treatment methods for chronic wounds which are difficult to heal are many, local treatment is one of the main means, but the clinical curative effect is not satisfactory. The chronic refractory wound surface is mainly used for resisting infection, improving nutrition and promoting chronic refractory wound surface.
At present, the treatment of chronic wounds has a plurality of treatment methods and means in clinic besides the traditional treatment method. Such as negative pressure therapy, moist burn cream, Platelet Rich Plasma (PRP), etc., and also growth factors, cytokine inhibitors and stimulators, skin substitutes, gene and stem cell therapy, extracellular matrix and angiogenesis stimulators, matrix metalloproteinase inhibitors, etc. But the new treatment method is not popularized yet, the cost is high, the price is high, and the treatment expense benefit ratio is low.
Therefore, the technical problem to be solved by the technical personnel in the field is how to provide a wound repair gel which can effectively promote the rapid repair of wound cells, improve the wound healing speed and improve the wound repair effect.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to effectively promote the rapid repair of wound cells, improve the speed of wound healing and improve the effect of wound repair. The invention provides a wound repair gel, which is prepared from the following materials: adding compound amino acid, glucose, polyvinyl alcohol and insulin according to the weight ratio; polyvinylpyrrolidone and gel additive are added according to the volume ratio.
According to a first embodiment of the invention, there is provided a wound repair gel:
a wound repair gel is prepared from the following materials: adding compound amino acid, glucose, polyvinyl alcohol and insulin according to the weight ratio; polyvinylpyrrolidone and gel additive are added according to the volume ratio.
Further, as a more preferred embodiment of the present invention, the preparation material of the repair gel further comprises: hydrogen peroxide is added according to the volume ratio.
Further, as a more preferred embodiment of the present invention, the preparation material of the repair gel further comprises: sodium benzoate and gentamicin are added according to the weight ratio.
Further, as a more preferred embodiment of the present invention, the gel additive is prepared by dissolving 10-20g of carbomer and 10-20g of triethanolamine in purified water.
Further, as a more preferred embodiment of the present invention, the preparation material of the repair gel further comprises: sodium chloride, calcium chloride and potassium chloride are added according to the weight ratio.
Further, as a more preferred embodiment of the present invention, the preparation material of the repair gel further comprises: dextran, glycerol and propylene glycol are added according to the weight ratio.
Further, as a more preferred embodiment of the present invention, it is prepared by: dissolving 0.6-0.8g of the compound amino acid, 3-5g of the glucose, 3-5g of the sodium chloride, 0.1-0.3g of the calcium chloride and 0.2-0.4g of the potassium chloride in 0.1-1.0% of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of a first group of nutrient solution; dissolving 0.5-2g of polyvinyl alcohol, 0.1-1 ml of insulin, 1-4g of glucan, 8-20g of glycerol and 3-10g of propylene glycol in 0.1-1.0% of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of a second group of cell proliferation and immune solution; dissolving 30-20 ml of 30% hydrogen peroxide solution in 0.1-1.0% polyvinylpyrrolidone aqueous solution according to volume ratio to obtain 100ml of third group oxygenation solution; 2-10g of sodium benzoate and 0.5-3mg of gentamicin are dissolved in 0.1-1.0% of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of fourth group anti-infection solution.
Further, as a more preferred embodiment of the present invention, the glucose is D-glucose; the glucan is beta-glucan.
Further, as a more preferred embodiment of the present invention, the complex amino acid includes: tryptophan, methionine, phenylalanine, threonine, valine, isoleucine, leucine, lysine; the weight ratio of the tryptophan to the methionine to the phenylalanine to the threonine to the valine to the isoleucine to the leucine to the lysine is 1:2:4:6:6:7:7:9, respectively.
According to a second embodiment of the present invention, there is provided a method of preparing a wound repair gel:
a preparation method of a wound repair gel comprises the following steps:
s1, preparing a nutrient component system: dissolving 0.6-0.8g of compound amino acid, 3-5g of D-glucose, 3-5g of sodium chloride, 0.1-0.3g of calcium chloride and 0.2-0.4g of potassium chloride in 0.1-1.0% of polyvinylpyrrolidone aqueous solution, and fully dissolving to obtain 100ml of a first group of nutrient solution;
s2, preparing a cell proliferation component system: dissolving 0.5-2g of polyvinyl alcohol, 0.1-1 ml of insulin, 1-4g of glucan, 8-20g of glycerol and 3-10g of propylene glycol in 0.1-1.0% of polyvinylpyrrolidone aqueous solution, and fully dissolving to obtain 100ml of a second group of cell proliferation and immune solution;
s3, preparing a blood cell oxygenation component system: dissolving 30-20 ml of 30% hydrogen peroxide solution in 0.1-1.0% polyvinylpyrrolidone aqueous solution, and mixing uniformly to obtain 100ml of a third group of oxygenated solution;
s4, preparing an anti-infection component system: 2-10g of sodium benzoate and 0.5-3mg of gentamicin are dissolved in 0.1-1.0% of polyvinylpyrrolidone water solution, and are fully dissolved to obtain 100ml of fourth group anti-infection solution;
s5, preparing a gel component system: dispersing 10-20g of carbomer in 900g of purified water of 800-; dissolving 10-20g triethanolamine in 70-170g purified water, mixing, slowly pouring into the carbomer solution, standing overnight, and stirring to obtain the fifth gel additive.
S6, preparing a wound repair gel: and uniformly stirring and mixing the first group of nutrient solution, the second group of cell proliferation and immune solution, the third group of oxygenation solution, the fourth group of anti-infection solution and the fifth group of gel additive according to the volume parts of 1:1:1:1:6 to obtain the wound repair gel.
Further, as a more preferred embodiment of the present invention, the glucose is D-glucose; the glucan is beta-glucan.
Further, as a more preferred embodiment of the present invention, the complex amino acid includes: tryptophan, methionine, phenylalanine, threonine, valine, isoleucine, leucine, lysine; the weight ratio of the tryptophan to the methionine to the phenylalanine to the threonine to the valine to the isoleucine to the leucine to the lysine is 1:2:4:6:6:7:7:9, respectively.
What needs to be added is that the preparation method of the wound repair gel further comprises the following steps:
s601, in the preparation process, the first group of nutrient solution, the second group of cell proliferation and immunization solution, the third group of oxygenation solution, the fourth group of anti-infection solution and the fifth group of gel additive are stored at low temperature so as to improve the quality of the final wound repair gel.
What needs to be added is that the preparation method of the wound repair gel further comprises the following steps:
s602 in the process of uniformly stirring and mixing the first group of nutrient solution, the second group of cell proliferation and immunity solution, the third group of oxygenation solution, the fourth group of anti-infection solution and the fifth group of gel additive, the mixing needs to be carried out at the solution temperature of 20-40 ℃ so as to improve the mixing speed of the first group of nutrient solution, the second group of cell proliferation and immunity solution, the third group of oxygenation solution, the fourth group of anti-infection solution and the fifth group of gel additive and improve the production efficiency.
What needs to be added is that the preparation method of the wound repair gel further comprises the following steps:
s301, ozone gas is introduced into the third group of oxygenation solution, and the oxidizability of the whole third group of oxygenation solution is increased.
According to a third embodiment of the invention, a wound autoblood repair gel is provided:
a wound surface autoblood repair gel is prepared from the following materials: equal volumes of the wound repair gel and autologous venous blood of the patient.
According to a fourth embodiment of the invention, a preparation method of the wound autoblood repair gel is provided:
a preparation method of wound surface autoblood repair gel comprises the following steps: s7, preparing wound surface autoblood repair gel: and fully mixing the venous blood of the wound patients with the same volume with the wound repair gel with the same volume to obtain the wound autoblood repair gel.
Furthermore, aiming at the defects that the prior PRP operation technology is complex, the components are single, the cost is high, and the wound surface is directly covered by autologous whole blood and bacteria are easy to breed and grow, the invention aims to provide the autologous blood gel for treating the chronic wound surface which is difficult to heal. The autoblood gel for wound surface application has simple preparation method and convenient application, and has the advantages of high-efficiency promotion of wound surface healing, broad-spectrum antibacterial property and good protection effect on wound surface. The autoblood gel comprises five components: a cell nutrition system consisting of eighteen kinds of amino acids and autoblood; a cell proliferation promoting and immune regulating system consisting of polyvinyl alcohol, insulin and beta-glucan; oxygen and an action system provided by low-dose hydrogen peroxide and an anti-infection system consisting of benzoic acid and gentamicin; a gel system consisting of carbomer and triethanolamine. The wound surface autoblood repair gel has complete functions and is designed according to the pathophysiology characteristics of wound surface healing. The components of the autoblood gel are respectively dissolved in polyvinylpyrrolidone (PVP) and then are uniformly mixed with carbomer gel components, so that the antagonism possibly generated by the components is reduced, meanwhile, the effective components can be slowly released, and the possible side effect is reduced.
Compared with the prior art, according to the technical scheme, a basic nutrition and energy system of cells is constructed by mixing compound amino acid, glucose and polyvinylpyrrolidone, a cell proliferation and immunity system is constructed by mixing polyvinyl alcohol, insulin and polyvinylpyrrolidone, and finally, a polyvinylpyrrolidone solution containing compound amino acid, glucose, polyvinyl alcohol and insulin is mixed with a gel additive to obtain the wound repair gel. The technical scheme provided by the application can effectively promote the rapid repair of the cells of the wound surface, improve the speed of wound surface healing and improve the effect of wound surface repair.
Drawings
FIG. 1 is a flow chart of a method of preparing a wound healing gel according to an embodiment of the present invention;
FIG. 2 is a flow chart of a method for preparing a wound autologous blood repair gel according to an embodiment of the present invention;
figure 3 is a graph of a comparison experiment of venous blood with different concentrations of hydrogen peroxide in an example of the present invention,
in the figure, A, B, C three groups of control groups are arranged above the wound surface in sequence, contain hydrogen peroxide with different doses, and are changed into bright red similar to arterial blood through oxygenation, D is venous blood of a patient, is dark red, is blood with high oxygenation, provides local oxygen supply for the wound surface, and is favorable for wound surface repair;
FIG. 4 is a schematic view of the wound surface before treatment with the wound surface autoblood repair gel of Experimental example 2 in an example of the present invention;
fig. 5 is a schematic view of the wound surface after the treatment of the wound surface autoblood repair gel of experimental example 2 in the embodiment of the present invention.
Detailed Description
In order to make those skilled in the art better understand the technical solutions in the present application, the technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application, and it is obvious that the described embodiments are only a part of the embodiments of the present application, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present application.
It will be understood that when an element is referred to as being "fixed" or "disposed" on another element, it can be directly on the other element or be indirectly disposed on the other element; when an element is referred to as being "connected to" another element, it can be directly connected to the other element or be indirectly connected to the other element.
It will be understood that the terms "length," "width," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," and the like, refer to an orientation or positional relationship illustrated in the drawings for convenience in describing the present application and to simplify description, and do not indicate or imply that the referenced device or element must have a particular orientation, be constructed and operated in a particular orientation, and thus should not be construed as limiting the present application.
Furthermore, the terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. In the description of the present application, "plurality" or "a plurality" means two or more unless specifically limited otherwise.
It should be understood that the structures, ratios, sizes, and the like shown in the drawings are only used for matching the disclosure of the specification, so as to be understood and read by those skilled in the art, and are not used to limit the practical limit conditions of the present application, so that the modifications of the structures, the changes of the ratio relationships, or the adjustment of the sizes, do not have the technical essence, and the modifications, the changes of the ratio relationships, or the adjustment of the sizes, are all within the scope of the technical contents disclosed in the present application without affecting the efficacy and the achievable purpose of the present application.
According to a first embodiment of the invention, there is provided a wound repair gel:
a wound repair gel is prepared from the following materials: adding compound amino acid, glucose, polyvinyl alcohol and insulin according to the weight ratio; polyvinylpyrrolidone and gel additive are added according to the volume ratio.
The application provides a technical scheme of wound repair gel. According to the technical scheme, a basic nutrition and energy system of cells is constructed by mixing compound amino acid, glucose and polyvinylpyrrolidone, a cell proliferation and immunity system is constructed by mixing polyvinyl alcohol, insulin and polyvinylpyrrolidone, and finally, a wound repair gel can be obtained by mixing a polyvinylpyrrolidone solution containing compound amino acid, glucose, polyvinyl alcohol and insulin with a gel additive. The technical scheme provided by the application can effectively promote the rapid repair of the cells of the wound surface, improve the speed of wound surface healing and improve the effect of wound surface repair.
Specifically, in the embodiment of the present invention, the preparation material of the repair gel further includes: hydrogen peroxide is added according to the volume ratio.
In this embodiment, hydrogen peroxide is added to the wound repair gel, so that sufficient oxygen can be supplied to the wound, and oxygen required in the wound cell repair process, that is, the cell proliferation repair effect of polyvinyl alcohol, insulin, and dextran, can be promoted.
Specifically, in the embodiment of the present invention, the preparation material of the repair gel further includes: sodium benzoate and gentamicin are added according to the weight ratio.
By adding sodium benzoate and gentamicin into the wound repair gel, the wound repair gel has anti-infection capability, so that the anti-infection capability of the wound is improved, and the rapid healing of the wound is promoted.
Specifically, in the embodiment of the invention, the gel additive is prepared by dissolving 10-20g of carbomer and 10-20g of triethanolamine in purified water.
It should be noted that the gel additive is prepared by mixing carbomer and triethanolamine with purified water, and this technical scheme is a scheme of a commonly used gel additive. In the embodiment, the adopted carbomer is a high molecular polymer, and can promote the first group of nutrient solution, the second group of cell proliferation and immune solution, the third group of oxygenation solution and the fourth group of anti-infection solution to be uniformly distributed in the carbomer, so that the carbomer can slowly release the medicament for the wound surface.
Specifically, in the embodiment of the present invention, the preparation material of the repair gel further includes: sodium chloride, calcium chloride and potassium chloride are added according to the weight ratio.
It is noted that basic inorganic nutrients required by human cells can be supplemented from the outside by supplementing sodium chloride, calcium chloride and potassium chloride, and the wound repair is promoted.
Specifically, in the embodiment of the present invention, the preparation material of the repair gel further includes: dextran, glycerol and propylene glycol are added according to the weight ratio.
The dextran is a polysaccharide, and can replace a part of whole blood in the blood transfusion process to be used as an expansion agent of the plasma volume, so that the combination of the wound repair gel and capillary vessels of the wound is promoted, and the medicine components of the wound repair gel are promoted to enter the wound.
Specifically, in the examples of the present invention, the preparation method thereof is: dissolving 0.6-0.8g of the compound amino acid, 3-5g of the glucose, 3-5g of the sodium chloride, 0.1-0.3g of the calcium chloride and 0.2-0.6g of the potassium chloride in 0.1-1.0% of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of a first group of nutrient solution; dissolving 0.5-2g of polyvinyl alcohol, 0.1-1 ml of insulin, 1-4g of glucan, 8-20g of glycerol and 3-10g of propylene glycol in 0.1-1.0% of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of a second group of cell proliferation and immune solution; 3-20 ml of 30% hydrogen peroxide solution is dissolved in 0.1-1.0% polyvinylpyrrolidone water solution according to the volume ratio to obtain 100ml of a third group of oxygenated solution; 2-10g of sodium benzoate and 0.5-3mg of gentamicin are dissolved in 0.1-1.0% of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of fourth group anti-infection solution.
The polyvinylpyrrolidone has excellent physiological inertia, does not participate in human metabolism, has excellent biocompatibility, and does not cause any stimulation to skin, mucous membrane, eyes and the like. Therefore, the wound repair gel provided by the application utilizes polyvinylpyrrolidone as an auxiliary material, can effectively promote the combination of components such as nutritional repair in the wound repair gel and the like with the wound, and promotes the rapid healing of the wound.
Specifically stated, in the present examples, the glucose is D-glucose; the glucan is beta-glucan.
Specifically stated, in the present examples, the complex amino acids include: tryptophan, methionine, phenylalanine, threonine, valine, isoleucine, leucine, lysine; the weight ratio of the tryptophan to the methionine to the phenylalanine to the threonine to the valine to the isoleucine to the leucine to the lysine is 1:2:4:6:6:7:7:9, respectively.
According to a second embodiment of the present invention, there is provided a method of preparing a wound repair gel:
a preparation method of a wound repair gel comprises the following steps:
s1, preparing a nutrient component system: dissolving 0.6-0.8g of compound amino acid, 3-5g of D-glucose, 3-5g of sodium chloride, 0.1-0.3g of calcium chloride and 0.2-0.6g of potassium chloride in 0.1-1.0% of polyvinylpyrrolidone aqueous solution, and fully dissolving to obtain 100ml of a first group of nutrient solution;
s2, preparing a cell proliferation component system: dissolving 0.5-2g of polyvinyl alcohol, 0.1-1 ml of insulin, 1-4g of glucan, 8-20g of glycerol and 3-10g of propylene glycol in 0.1-1.0% of polyvinylpyrrolidone aqueous solution, and fully dissolving to obtain 100ml of a second group of cell proliferation and immune solution;
s3, preparing a blood cell oxygenation component system: dissolving 3-20 ml of 30% hydrogen peroxide solution in 0.1-1.0% polyvinylpyrrolidone aqueous solution, and mixing uniformly to obtain 100ml of a third group of oxygenated solution;
s4, preparing an anti-infection component system: 2-10g of sodium benzoate and 0.5-3mg of gentamicin are dissolved in 0.1-1.0% of polyvinylpyrrolidone water solution, and are fully dissolved to obtain 100ml of fourth group anti-infection solution;
s5, preparing a gel component system: dispersing 10-20g of carbomer in 900g of purified water of 800-; dissolving 10-20g triethanolamine in 70-170g purified water, mixing, slowly pouring into the carbomer solution, standing overnight, and stirring to obtain the fifth gel additive.
S6, preparing a wound repair gel: and uniformly stirring and mixing the first group of nutrient solution, the second group of cell proliferation and immune solution, the third group of oxygenation solution, the fourth group of anti-infection solution and the fifth group of gel additive according to the volume parts of 1:1:1:1:6 to obtain the wound repair gel.
The application also provides a preparation method of the wound repair gel. The preparation method comprises the steps of respectively dissolving a first component (compound amino acid, glucose, sodium chloride, calcium chloride and potassium chloride), a second component (polyvinyl alcohol, insulin, glucan, glycerol and propylene glycol), a third component (hydrogen peroxide solution) and a fourth component (sodium benzoate and gentamicin) in a polyvinylpyrrolidone (PVP) solution with the same volume, mixing the obtained first group of nutrient solution, second group of cell proliferation and immune solution, third group of oxygenation solution and fourth group of anti-infection solution with a gel additive to obtain the wound repair gel. The wound repair gel prepared by the scheme can effectively promote the rapid repair of wound cells, improve the speed of wound healing and improve the effect of wound repair.
Specifically stated, in the present examples, the glucose is D-glucose; the glucan is beta-glucan.
Specifically stated, in the present examples, the complex amino acids include: tryptophan, methionine, phenylalanine, threonine, valine, isoleucine, leucine, lysine; the weight ratio of the tryptophan to the methionine to the phenylalanine to the threonine to the valine to the isoleucine to the leucine to the lysine is 1:2:4:6:6:7:7:9, respectively.
According to a third embodiment of the invention, a wound autoblood repair gel is provided:
a wound surface autoblood repair gel is prepared from the following materials: equal volumes of the wound repair gel of the first embodiment and patient autologous venous blood.
It should be added that, in recent years, research shows that autologous whole blood has a good effect in the treatment of chronic wounds, i.e., a small amount of blood is extracted from human venous blood and uniformly applied to the wounds, so that the wounds can be quickly healed, and the research is considered to be related to various growth factors derived from blood. Autologous whole blood is known to contain substances such as growth factors, erythrocytes, leukocytes, platelets, serum, fibrin, and the like. Kushnir et al believe that in the early stages of wound repair, the blood clot can reestablish hemostasis and protect the wound through its fibrin scaffold, which acts as a temporary matrix, promoting angiogenesis, while carrying associated cells and factors promoting healing and inflammation. In clinical research, the scholars in China, namely Chuan Qinni, Liu Xiuqing and the like, draw venous blood of a diabetic and directly apply the venous blood on the wound surface of a diabetic foot, so that the venous blood is better in treatment effect. Autologous whole blood is directly applied to the surface of a wound which is difficult to heal, blood cells lack nutrition support, the survival period is short, and simultaneously, bacteria are easy to grow and reproduce to cause the infection of the wound surface.
According to a fourth embodiment of the invention, a preparation method of the wound autoblood repair gel is provided:
a preparation method of wound surface autoblood repair gel comprises the following steps: s7, preparing wound surface autoblood repair gel: and fully mixing the venous blood of the wound patients with the same volume with the wound repair gel with the same volume to obtain the wound autoblood repair gel.
Example 1
A wound repair gel is prepared from the following materials: adding compound amino acid, glucose, polyvinyl alcohol and insulin according to the weight ratio; polyvinylpyrrolidone and gel additive are added according to the volume ratio.
Example 2
Example 1 was repeated except that the preparation material of the repair gel further included: hydrogen peroxide is added according to the volume ratio.
Example 3
Example 2 was repeated except that the materials for preparing the repair gel further included: sodium benzoate and gentamicin are added according to the weight ratio.
Example 4
Example 3 was repeated except that the gel additive was prepared by dissolving 15g of carbomer and 15g of triethanolamine in 970g of purified water.
Example 5
Example 4 was repeated, except that the preparation material of the repair gel further included: sodium chloride, calcium chloride and potassium chloride are added according to the weight ratio.
Example 6
Example 5 was repeated, except that the preparation material of the repair gel further included: dextran, glycerol and propylene glycol are added according to the weight ratio.
Example 7
Example 6 was repeated except that the preparation was carried out by: 657mg of the compound amino acid, 4.5g of the glucose, 4.5g of the sodium chloride, 0.2g of the calcium chloride and 0.4g of the potassium chloride are dissolved in 1 percent of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of a first group of nutrient solution; dissolving 1g of polyvinyl alcohol, 50 units of insulin, 2g of glucan, 10g of glycerol and 5g of propylene glycol in 1% of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of a second group of cell proliferation and immune solution; dissolving 10 ml of 30% hydrogen peroxide solution in 1% polyvinylpyrrolidone aqueous solution according to the volume ratio to obtain 100ml of a third group of oxygenated solution; 5g of sodium benzoate and 1.5mg of gentamicin are dissolved in 1 percent of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of fourth group anti-infection solution.
Example 8
Example 7 was repeated except that the glucose was D-glucose; the glucan is beta-glucan. The compound amino acid comprises: tryptophan, methionine, phenylalanine, threonine, valine, isoleucine, leucine, lysine; the weight ratio of the tryptophan to the methionine to the phenylalanine to the threonine to the valine to the isoleucine to the leucine to the lysine is 1:2:4:6:6:7:7:9, respectively.
Example 9
A preparation method of a wound repair gel comprises the following steps:
s1, preparing a nutrient component system: 657mg of compound amino acid, 4.5g of glucose, 4.5g of sodium chloride, 0.2g of calcium chloride and 0.4g of potassium chloride are dissolved in 1% polyvinylpyrrolidone aqueous solution, and are fully dissolved to obtain 100ml of a first group of nutrient solution;
s2, preparing a cell proliferation component system: dissolving 1g of the polyvinyl alcohol, 50 units of the insulin, 2g of the glucan, 10g of the glycerol and 5g of the propylene glycol in a 1% polyvinylpyrrolidone aqueous solution, and fully dissolving to obtain 100ml of a second group of cell proliferation and immune solution;
s3, preparing a blood cell oxygenation component system: dissolving 10 ml of 30% hydrogen peroxide solution in 1% polyvinylpyrrolidone aqueous solution, and uniformly mixing to obtain 100ml of a third group of oxygenated solution;
s4, preparing an anti-infection component system: dissolving 5g of sodium benzoate and 1.5mg of gentamicin in 1% of polyvinylpyrrolidone aqueous solution, and fully dissolving to obtain 100ml of fourth group anti-infection solution;
s5, preparing a gel component system: dispersing 15g of carbomer in 850g of purified water, standing overnight, and obtaining a carbomer solution standing overnight after the carbomer is fully and uniformly dispersed; dissolving 15g of triethanolamine in 120g of purified water, uniformly mixing, slowly pouring into the carbomer solution standing overnight, and uniformly stirring to obtain a fifth group of gel additives.
S6, preparing a wound repair gel: and uniformly stirring and mixing the first group of nutrient solution, the second group of cell proliferation and immune solution, the third group of oxygenation solution, the fourth group of anti-infection solution and the fifth group of gel additive according to the volume parts of 1:1:1:1:6 to obtain the wound repair gel.
Example 10
Example 9 was repeated except that the glucose was D-glucose; the glucan is beta-glucan. The compound amino acid comprises: tryptophan, methionine, phenylalanine, threonine, valine, isoleucine, leucine, lysine; the weight ratio of the tryptophan to the methionine to the phenylalanine to the threonine to the valine to the isoleucine to the leucine to the lysine is 1:2:4:6:6:7:7:9, respectively.
Example 11
A wound surface autoblood repair gel is prepared from the following materials: equal volumes of the wound repair gel and autologous venous blood of the patient.
Example 12
A preparation method of wound surface autoblood repair gel comprises the following steps: s7, preparing wound surface autoblood repair gel: and fully mixing the venous blood of the wound patients with the same volume with the wound repair gel with the same volume to obtain the wound autoblood repair gel.
Experimental example 1:
referring to fig. 3, venous blood of a wound patient is mixed with wound autoblood repair gel with the same volume, so that the venous blood is instantly changed into arterial blood with complete oxygenation, and the wound autoblood repair gel covers the local part of the wound, can improve the anoxic state of the wound and is beneficial to wound healing. In the sample with venous blood added with hydrogen peroxide, three groups of concentrations of hydrogen peroxide are designed to be mixed with the venous blood in equal volumes:
it can be seen from the figure that venous blood, to which a 0.3% equal volume of hydrogen peroxide solution was added, was in substantial agreement with arterial blood. The hydrogen peroxide can be beneficial to improving the oxygen content of venous blood of a patient in the wound surface autoblood repair gel, improving the blood activity and promoting the rapid repair of the wound surface.
Experimental example 2:
and (5) an effect experiment for promoting wound healing. 20 diabetic skin chronic wound patients eligible for hospitalization were selected. According to the grouping method of a random number table, 20 patients are randomly divided into a control group and an experimental group, wherein each group comprises 10 patients, the control group is subjected to silkworm food debridement and foam dressing treatment, the experimental group is autologous blood repair gel, the research is approved by the ethical committee of the third hospital, and all patients sign informed consent. The results of diabetic foot wound healing are shown in the table below and in figures 4-5 below. The experimental result shows that the wound surface autoblood repair gel can effectively promote the healing of the wound surface of the diabetic foot when used for treating the diabetic foot.
TABLE 1 comparison of wound healing rates before and after treatment (x + -s)
Experimental example 3:
effect experiment for promoting wound surface capillary vessel proliferation. Following experimental example 2, capillary blood vessels were counted in two groups of patients treated with wound autoblood repair gel therapy on days 0 and 15: two groups of patients are treated on the 0 th day and the 15 th day, central granulation tissues of wound surfaces are taken and placed in 10% formaldehyde solution, the tissues are stored at 4 ℃, embedded and sliced, the slices are observed under a microscope, 5 areas with the most capillaries under a low power microscope are found, capillaries under a high power microscope (400 x) are counted, and the average value under the high power microscope is taken as the number of the capillaries of the slices. The wound surface capillary vessel proliferation of the facial autoblood repair gel group was significantly increased, and the results are shown in table 2.
TABLE 2 comparison of capillary counts before and after treatment (x + -s)
Experimental example 4:
and (3) an antibacterial effect experiment of the wound surface autoblood repair gel. According to appendix C of GB15979-2002 of hygienic products for disposable use, 5mL of samples are respectively added into three test tubes, 100 μ L of each bacterial suspension of staphylococcus aureus, escherichia coli and candida albicans is respectively mixed with the samples, timing is started, after action is performed for 2min, 5min, 10min and 20min, 0.5mL of the samples are taken out and added into the test tube containing 4.5mL of PBS to be fully mixed, 0.5mL of the samples are respectively absorbed and placed into two plates, the two plates are poured by 15mL of nutrient agar or a Sabouraud's medium cooled to 40-45 ℃, the plates are shaken to be fully mixed, the plates are placed into a constant temperature incubator at 35 ℃ to be cultured for 48 hours after solidification, and then colony counting is carried out. And (4) comparing with a blank control group, and calculating the bacteriostasis rate. The experimental result shows that the inhibition rate of the wound surface autoblood repair gel on staphylococcus aureus, escherichia coli and candida albicans is 100%.
Experimental example 5:
in vitro cytotoxicity test. And (3) removing original culture solution from 9 cultured L-929 single-layer cell culture dishes according to an in vitro cytotoxicity test GB/T16886.5-2017, replacing 0.8mL of fresh culture medium, respectively adding a positive control, a negative control and a sample to be detected, and continuously culturing for 24 hours at 37 ℃ under the condition of 5% CO 2. After 24h incubation, 3 dishes per group were taken and cell morphology observation and toxic area measurement were performed under a microscope. Under the experimental condition, the wound surface autoblood repair gel has no toxicity to L-929 cells, and the cell reaction is 0 grade.
Experimental example 6:
skin irritation test. According to GB/T16886.10-2005, 3 healthy test rabbits were shaved 24 hours before the test to avoid skin injury. The prepared test article is directly pasted on one side of the back of the experimental rabbit at the experimental part, and the other side is pasted with a blank control (0.9% sodium chloride injection) by the same method, and is immediately fixed. After 4h of fixation the patch was removed and the test site of the patch was marked. The application was continued for 14 days. After lh, 24h, 48h and 72h after removal of the patch, the test site and its skin tissue reactions including erythema, edema and necrosis were observed, and after 72h, the test article and the control article were applied daily by the same procedure as above, and the contact site was recorded each time after lh after removal of the patch and before re-contact. After the last contact, each contact site was recorded lh, 24h, 48h and 72h after removal of the patch, respectively. The scores were graded according to the standard scores of 0, 1, 2, 3 and 4 according to the occurrence of erythema and edema. Under the experimental condition, the cumulative stimulation index of the wound surface autoblood repair gel to multiple skin experiment stimulation experiments of rabbits is 0, and the reaction type is extremely slight.
Experimental example 7:
2) according to GB/T16886.10-2005, 3 healthy test rabbits were shaved 24 hours before the test to avoid skin injury. The prepared test article is directly pasted on one side of the back of the experimental rabbit at the experimental part, and the other side is pasted with a blank control (0.9% sodium chloride injection) by the same method, and is immediately fixed. After 4h of fixation the patch was removed and the test site of the patch was marked. The application was continued for 14 days. After lh, 24h, 48h and 72h after removal of the patch, the test site and its skin tissue reactions including erythema, edema and necrosis were observed, and after 72h, the test article and the control article were applied daily by the same procedure as above, and the contact site was recorded each time after lh after removal of the patch and before re-contact. After the last contact, each contact site was recorded lh, 24h, 48h and 72h after removal of the patch, respectively. The scores were graded according to the standard scores of 0, 1, 2, 3 and 4 according to the occurrence of erythema and edema. Under the experimental condition, the cumulative stimulation index of the wound surface autoblood repair gel to multiple skin experiment stimulation experiments of rabbits is 0, and the reaction type is extremely slight.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (10)
1. A wound repair gel is characterized in that the preparation material of the repair gel comprises: adding compound amino acid, glucose, polyvinyl alcohol and insulin according to the weight ratio; polyvinylpyrrolidone and gel additive are added according to the volume ratio.
2. The wound repair gel of claim 1, wherein the preparation material of the repair gel further comprises: hydrogen peroxide is added according to the volume ratio; and/or
The preparation material of the repair gel also comprises: sodium benzoate and gentamicin are added according to the weight ratio.
3. The wound repair gel of claim 2, wherein the gel additive is prepared by dissolving 10-20g carbomer and 10-20g triethanolamine in purified water.
4. The wound repair gel of claim 3, wherein the preparation material of the repair gel further comprises: sodium chloride, calcium chloride and potassium chloride are added according to the weight ratio; and/or
The preparation material of the repair gel also comprises: dextran, glycerol and propylene glycol are added according to the weight ratio.
5. A wound repair gel according to claim 4, characterized in that it is prepared by:
dissolving 0.6-0.8g of the compound amino acid, 3-5g of the glucose, 3-5g of the sodium chloride, 0.1-0.3g of the calcium chloride and 0.2-0.6g of the potassium chloride in 0.1-1.0% of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of a first group of nutrient solution;
dissolving 0.5-2g of polyvinyl alcohol, 0.1-1 ml of insulin, 1-4g of glucan, 8-20g of glycerol and 3-10g of propylene glycol in 0.1-1.0% of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of a second group of cell proliferation and immune solution;
3-20 ml of 30% hydrogen peroxide solution is dissolved in 0.1-1.0% polyvinylpyrrolidone water solution according to the volume ratio to obtain 100ml of a third group of oxygenated solution;
2-10g of sodium benzoate and 0.5-3mg of gentamicin are dissolved in 0.1-1.0% of polyvinylpyrrolidone aqueous solution according to the weight ratio to obtain 100ml of fourth group anti-infection solution.
6. The wound repair gel of any one of claims 1, 2, 4, 5, wherein the glucose is D-glucose; the glucan is beta-glucan; and/or
The compound amino acid comprises: tryptophan, methionine, phenylalanine, threonine, valine, isoleucine, leucine, lysine; the weight ratio of the tryptophan to the methionine to the phenylalanine to the threonine to the valine to the isoleucine to the leucine to the lysine is 1:2:4:6:6:7:7:9, respectively.
7. A method of preparing a wound repair gel or a wound repair gel according to any one of claims 1 to 6, comprising the steps of:
s1, preparing a nutrient component system: dissolving 0.6-0.8g of compound amino acid, 3-5g of D-glucose, 3-5g of sodium chloride, 0.1-0.3g of calcium chloride and 0.2-0.6g of potassium chloride in 0.1-1.0% of polyvinylpyrrolidone aqueous solution, and fully dissolving to obtain 100ml of a first group of nutrient solution;
s2, preparing a cell proliferation component system: dissolving 0.5-2g of polyvinyl alcohol, 0.1-1 ml of insulin, 1-4g of glucan, 8-20g of glycerol and 3-10g of propylene glycol in 0.1-1.0% of polyvinylpyrrolidone aqueous solution, and fully dissolving to obtain 100ml of a second group of cell proliferation and immune solution;
s3, preparing a blood cell oxygenation component system: dissolving 3-20 ml of 30% hydrogen peroxide solution in 0.1-1.0% polyvinylpyrrolidone aqueous solution, and mixing uniformly to obtain 100ml of a third group of oxygenated solution;
s4, preparing an anti-infection component system: 2-10g of sodium benzoate and 0.5-3mg of gentamicin are dissolved in 0.1-1.0% of polyvinylpyrrolidone water solution, and are fully dissolved to obtain 100ml of fourth group anti-infection solution;
s5, preparing a gel component system: dispersing 10-20g of carbomer in 900g of purified water of 800-; dissolving 10-20g triethanolamine in 70-170g purified water, mixing, slowly pouring into the carbomer solution, standing overnight, and stirring to obtain the fifth gel additive.
S6, preparing a wound repair gel: and uniformly stirring and mixing the first group of nutrient solution, the second group of cell proliferation and immune solution, the third group of oxygenation solution, the fourth group of anti-infection solution and the fifth group of gel additive according to the volume parts of 1:1:1:1:6 to obtain the wound repair gel.
8. The method according to claim 7, wherein the glucose is D-glucose; the glucan is beta-glucan; and/or
The compound amino acid comprises: tryptophan, methionine, phenylalanine, threonine, valine, isoleucine, leucine, lysine; the weight ratio of the tryptophan to the methionine to the phenylalanine to the threonine to the valine to the isoleucine to the leucine to the lysine is 1:2:4:6:6:7:7:9, respectively.
9. A wound autologous blood repair gel according to any one of claims 1 to 6, wherein the preparation material of the autologous blood repair gel comprises:
equal volumes of the wound repair gel of any one of claims 1-6 and autologous venous blood of a patient.
10. A wound healing gel preparation method based on the wound healing gel preparation method of claim 7 or 8, wherein the wound healing gel preparation method comprises:
s7, preparing wound surface autoblood repair gel: and fully mixing the venous blood of the wound patients with the same volume with the wound repair gel with the same volume to obtain the wound autoblood repair gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110858408.2A CN113975457A (en) | 2021-07-28 | 2021-07-28 | Wound repair gel, wound autoblood repair gel and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110858408.2A CN113975457A (en) | 2021-07-28 | 2021-07-28 | Wound repair gel, wound autoblood repair gel and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113975457A true CN113975457A (en) | 2022-01-28 |
Family
ID=79735092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110858408.2A Pending CN113975457A (en) | 2021-07-28 | 2021-07-28 | Wound repair gel, wound autoblood repair gel and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113975457A (en) |
-
2021
- 2021-07-28 CN CN202110858408.2A patent/CN113975457A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2059206B1 (en) | Dry wound dressing and drug delivery system | |
| AU2020101591A4 (en) | A thermosensitive gel, preparation method and application thereof | |
| CN103083226B (en) | The preparation of fibroblast growth factor-1 modifier gel and the application in diabetic foot | |
| CN103405747B (en) | Preparation method for alanyl-glutamine biological adhesive preparation as well as product and application of preparation | |
| UA72735C2 (en) | Pharmaceutical composition for treatment of patients in intensive care units and method for its preparation | |
| CN113230449B (en) | Glucose and enzyme double-response dressing for treating chronic wound surface of diabetes and preparation method thereof | |
| CN113577366B (en) | Dry film dressing for promoting rapid healing of difficult-to-heal wounds of diabetes and preparation method thereof | |
| CN108498855B (en) | Antibacterial hemostatic sol and preparation method thereof | |
| CN112999410B (en) | Nano oxygenated hydrogel healing-promoting dressing containing perfluorodecalin and preparation method and application thereof | |
| Barakat et al. | Management of massive intractable hematuria A simple method | |
| CN113975457A (en) | Wound repair gel, wound autoblood repair gel and preparation method | |
| CN108354951B (en) | Oxygen-enriched gel for promoting wound healing, preparation method and application | |
| EP2389924B1 (en) | An eyedrops of the deproteinized calf blood extract | |
| CN111265477B (en) | Carbazochrome sodium sulfonate and sodium chloride injection and preparation method thereof | |
| WO2006026604A2 (en) | Methods for promoting wound healing | |
| CN106562953A (en) | Application of hydroxysafflor yellow A in preparing medicine for treating diabetic foot ulceration, medicine and medicine preparation method | |
| Zheng et al. | Heat sterilization of peritoneal dialysis solutions influences ingestive behavior in non-uremic rats | |
| Atiyeh et al. | The efficacy of moisture-retentive ointment in the management of cutaneous wounds and ulcers: A multicenter clinical trial | |
| RU2209074C2 (en) | Method for treating burns | |
| CN117653736A (en) | Tissue repair in-situ gel drop and preparation method thereof | |
| RU2735708C1 (en) | Method of simulating an infected wound in rats with background of long-term current diabetes mellitus | |
| CN111658763B (en) | Gynecological antibacterial gel and preparation method thereof | |
| RU94849U1 (en) | MEDICAL BANDAGE | |
| EP1776960B1 (en) | Use of collagen in combination with oxygen- and ozone-releasing perfluorocarbons for the preparation of a medicament for the treatment of skin lesions | |
| CN113398064A (en) | Medical copper oxide spray and manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |